Cassava Sciences Inc (SAVA) USD0.001
Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing drug for the treatment of nervous system disorders. The Company is ocused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Its drug candidate, PTI-125, is a small molecule that targets an altered form of a scaffolding protein called filamin A (FLNA). The Company is also developing an experimental biomarker/diagnostic, PTI-125Dx. It is developing PTI-125Dx to detect Alzheimer’s disease with a blood test.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.